Management of diabetic macular edema in Japan: a review and expert opinion

Hiroko Terasaki, Yuichiro Ogura, Shigehiko Kitano, Taiji Sakamoto, Toshinori Murata, Akito Hirakata, Tatsuro Ishibashi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50–69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. However, to achieve sustained long-term improvement in visual acuity, conventional laser photocoagulation, vitrectomy and steroid therapy are also expected to play a role in the treatment of DME. This review summarizes the epidemiology and pathology of diabetic retinopathy and DME, evaluates the findings regarding the diagnosis and treatment of DME, and underscores the importance of systemic management of the disease in the context of the current health care situation in Japan. Finally, the unmet needs of patients with DME and prospects for research are discussed. The weight of evidence suggests that it is important to establish a multipronged treatment strategy centered on anti-VEGF therapy.

Original languageEnglish
JournalJapanese Journal of Ophthalmology
Volume62
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Macular Edema
Expert Testimony
Japan
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Therapeutics
Light Coagulation
Vision Disorders
Vitrectomy
Diabetes Complications
Disease Management
Visual Acuity
Epidemiology
Lasers
Steroids
Pathology
Delivery of Health Care
Weights and Measures
Research

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Management of diabetic macular edema in Japan : a review and expert opinion. / Terasaki, Hiroko; Ogura, Yuichiro; Kitano, Shigehiko; Sakamoto, Taiji; Murata, Toshinori; Hirakata, Akito; Ishibashi, Tatsuro.

In: Japanese Journal of Ophthalmology, Vol. 62, No. 1, 01.01.2018.

Research output: Contribution to journalReview article

Terasaki, Hiroko ; Ogura, Yuichiro ; Kitano, Shigehiko ; Sakamoto, Taiji ; Murata, Toshinori ; Hirakata, Akito ; Ishibashi, Tatsuro. / Management of diabetic macular edema in Japan : a review and expert opinion. In: Japanese Journal of Ophthalmology. 2018 ; Vol. 62, No. 1.
@article{4ed36fe585e14c9b832883aef01e64f4,
title = "Management of diabetic macular edema in Japan: a review and expert opinion",
abstract = "Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50–69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. However, to achieve sustained long-term improvement in visual acuity, conventional laser photocoagulation, vitrectomy and steroid therapy are also expected to play a role in the treatment of DME. This review summarizes the epidemiology and pathology of diabetic retinopathy and DME, evaluates the findings regarding the diagnosis and treatment of DME, and underscores the importance of systemic management of the disease in the context of the current health care situation in Japan. Finally, the unmet needs of patients with DME and prospects for research are discussed. The weight of evidence suggests that it is important to establish a multipronged treatment strategy centered on anti-VEGF therapy.",
author = "Hiroko Terasaki and Yuichiro Ogura and Shigehiko Kitano and Taiji Sakamoto and Toshinori Murata and Akito Hirakata and Tatsuro Ishibashi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10384-017-0537-6",
language = "English",
volume = "62",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Management of diabetic macular edema in Japan

T2 - a review and expert opinion

AU - Terasaki, Hiroko

AU - Ogura, Yuichiro

AU - Kitano, Shigehiko

AU - Sakamoto, Taiji

AU - Murata, Toshinori

AU - Hirakata, Akito

AU - Ishibashi, Tatsuro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50–69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. However, to achieve sustained long-term improvement in visual acuity, conventional laser photocoagulation, vitrectomy and steroid therapy are also expected to play a role in the treatment of DME. This review summarizes the epidemiology and pathology of diabetic retinopathy and DME, evaluates the findings regarding the diagnosis and treatment of DME, and underscores the importance of systemic management of the disease in the context of the current health care situation in Japan. Finally, the unmet needs of patients with DME and prospects for research are discussed. The weight of evidence suggests that it is important to establish a multipronged treatment strategy centered on anti-VEGF therapy.

AB - Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50–69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. However, to achieve sustained long-term improvement in visual acuity, conventional laser photocoagulation, vitrectomy and steroid therapy are also expected to play a role in the treatment of DME. This review summarizes the epidemiology and pathology of diabetic retinopathy and DME, evaluates the findings regarding the diagnosis and treatment of DME, and underscores the importance of systemic management of the disease in the context of the current health care situation in Japan. Finally, the unmet needs of patients with DME and prospects for research are discussed. The weight of evidence suggests that it is important to establish a multipronged treatment strategy centered on anti-VEGF therapy.

UR - http://www.scopus.com/inward/record.url?scp=85037611264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037611264&partnerID=8YFLogxK

U2 - 10.1007/s10384-017-0537-6

DO - 10.1007/s10384-017-0537-6

M3 - Review article

C2 - 29210010

AN - SCOPUS:85037611264

VL - 62

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 1

ER -